Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Coverage of CGHS cities has expanded from 25 cities in 2014 to 80 in 2023
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Under the terms of the VPPA, IGNIS will produce renewable energy equal to Lonza’s electricity needs across Switzerland and the European Union.
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
Strategies aimed at solving the current overdose epidemic must go beyond the identification of risk
Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques
Subscribe To Our Newsletter & Stay Updated
